MRKFDA Approval•businesswire•
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Sentiment:Positive (80)
Summary
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 9, 2025 by businesswire